ChemotherapyFDA-approvedSecond-line
FOLFIRI
Generic name: irinotecan
How it works
Inhibits topoisomerase I, an enzyme involved in DNA replication, causing cancer cell death.
Cancer types
Efficacy
Studies show that FOLFIRI can achieve response rates of around 20% in patients with metastatic colorectal cancer.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Adagrasib in Combination with Cetuximab and Irinotecan for Colorectal Cancer | Colorectal Cancer | phase-1 | — | Source → |
| Testing a New Treatment for Small Cell Lung Cancer | Lung Cancer | phase-1 | — | Source → |
| Testing a New Cancer Drug with Chemotherapy for Advanced Stomach and Intestine Cancers | Colorectal Cancer | phase-1 | — | Source → |
| Second-Line Treatment for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | — | Source → |
| Testing Chemo-Immunotherapy for Pancreatic Cancer | Pancreatic Cancer | phase-2 | — | Source → |
| New Treatment Combination Shows Promise for Metastatic Colorectal Cancer | Colorectal Cancer | phase-2 | The objective response rate was 18.3%, and the disease control rate was 83.3%. | Source → |
| Combining Nanoparticles and Medication to Boost Pancreatic Cancer Treatment | Pancreatic Cancer | animal-study | — | Source → |
| Combining Cancer Drugs Improves Immune Response in Lab Experiments | Colorectal Cancer | lab-study | This neutrophil-based formulation resulted in a >4-fold increase in the ratios of the amount of both IRI and GAL accumulated in tumors to the dosage administration. | Source → |
| Engineered Nanocarriers Improve Irinotecan Delivery for Colon Cancer | Colorectal Cancer | lab-study | The P-DSPE-PEG-Ir LP exhibited significant tumor growth delay as compared to untreated and blank formulation-treated groups. | Source → |
| New Treatment Combination Shows Promise for Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | The 6-month progression-free survival rate was 58.8%. | Source → |
| New Treatment Shows Promise for Advanced Pancreatic Cancer | Pancreatic Cancer | meta-analysis | The use of nal-IRI resulted in significantly improved progression-free survival (pooled mean difference=1.01 months, 95% confidence interval [CI]=0.97-1.05, p<0.01) and overall survival (pooled mean difference=0.29 months, 95%CI=0.18-0.39, p<0.01), as well as significantly better overall response rate (pooled odds ratio=2.06, 95%CI=1.30-3.27, p=0.002) compared to other second-line regimens. | Source → |
| Comparing Cancer Treatments for Colorectal Cancer Patients | Colorectal Cancer | phase-3 | The expected survival times were 20.9 months for FOLFIRI, 29.9 months for Bmab, 27.8 months for Cmab, and 22.6 months for Pmab. | Source → |
| New Study Helps Optimize Chemotherapy for Colorectal Cancer Patients | Colorectal Cancer | phase-1 | — | Source → |
| Comparing Two Cancer Treatments in Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | There was no significant difference in median overall survival between treatment groups (9.1 months vs 10.1 months). | Source → |
| Liposomal Irinotecan in Biliary Tract Cancer: A Meta-Analysis | Pancreatic Cancer | meta-analysis | The combination therapy exhibited a statistically significant decrease in the risk of progression (hazard ratio 0.70; 95% confidence interval 0.50-0.97) | Source → |
| Rare Cancer Patient Shows Complete Response to Chemotherapy | Pancreatic Cancer | observational | — | Source → |
| Veliparib with FOLFIRI Fails to Improve Survival in Metastatic Pancreatic Cancer | Pancreatic Cancer | phase-2 | Median overall survival was 5.4 versus 6.5 months, and median progression-free survival was 2.1 versus 2.9 months with veliparib versus control. | Source → |
| Irinotecan Efficacy in Second-Line Lung Cancer Treatment | Lung Cancer | phase-2 | The patient's median progression-free survival was 3.8 (3.4-4.4) months, and median overall survival was 8.1 (6.5-10.9) months. | Source → |
| Combining Metformin and Irinotecan for Refractory Colorectal Cancer | Colorectal Cancer | phase-2 | The disease control rate was 41% at 12 weeks. | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.